ERBB2 and neoplasm: HER2 overexpression in EO-CRC may drive tumor aggressiveness through activation of key oncogenic pathways, including phosphoinositide 3-kinase (PI3K)/AKT and mitogen-activated protein kinase (MAPK) signaling, which promote cell proliferation, survival, and metastasis [41,42].